October 25, 2018 / 11:39 AM / a month ago

Celgene posts 9.5 percent rise in third-quarter profit

Oct 25 (Reuters) - Celgene Corp on Thursday reported a 9.5 percent increase in third-quarter profit, led by higher sales of its flagship cancer drug, Revlimid, and strong demand for psoriasis treatment Otezla.

The U.S. biotech company said net income rose to $1.08 billion, or $1.50 per share, in the quarter ended Sept. 30, from $988 million, or $1.21 per share, a year earlier.

Total revenue jumped 18.4 percent to $3.89 billion. (Reporting by Tamara Mathias in Bengaluru; Editing by Maju Samuel)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below